1
|
Lacaze P, Marquina C, Tiller J, Brotchie A, Kang YJ, Merritt MA, Green RC, Watts GF, Nowak KJ, Manchanda R, Canfell K, James P, Winship I, McNeil JJ, Ademi Z. Combined population genomic screening for three high-risk conditions in Australia: a modelling study. EClinicalMedicine 2023; 66:102297. [PMID: 38192593 PMCID: PMC10772163 DOI: 10.1016/j.eclinm.2023.102297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 10/12/2023] [Accepted: 10/13/2023] [Indexed: 01/10/2024] Open
Abstract
Background No previous health-economic evaluation has assessed the impact and cost-effectiveness of offering combined adult population genomic screening for mutliple high-risk conditions in a national public healthcare system. Methods This modeling study assessed the impact of offering combined genomic screening for hereditary breast and ovarian cancer, Lynch syndrome and familial hypercholesterolaemia to all young adults in Australia, compared with the current practice of clinical criteria-based testing for each condition separately. The intervention of genomic screening, assumed as an up-front single cost in the first annual model cycle, would detect pathogenic variants in seven high-risk genes. The simulated population was 18-40 year-olds (8,324,242 individuals), modelling per-sample test costs ranging AU$100-$1200 (base-case AU$200) from the year 2023 onwards with testing uptake of 50%. Interventions for identified high-risk variant carriers follow current Australian guidelines, modelling imperfect uptake and adherence. Outcome measures were morbidity and mortality due to cancer (breast, ovarian, colorectal and endometrial) and coronary heart disease (CHD) over a lifetime horizon, from healthcare-system and societal perspectives. Outcomes included quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER), discounted 5% annually (with 3% discounting in scenario analysis). Findings Over the population lifetime (to age 80 years), the model estimated that genomic screening per-100,000 individuals would lead to 747 QALYs gained by preventing 63 cancers, 31 CHD cases and 97 deaths. In the total model population, this would translate to 31,094 QALYs gained by preventing 2612 cancers, 542 non-fatal CHD events and 4047 total deaths. At AU$200 per-test, genomic screening would require an investment of AU$832 million for screening of 50% of the population. Our findings suggest that this intervention would be cost-effective from a healthcare-system perspective, yielding an ICER of AU$23,926 (∼£12,050/€14,110/US$15,345) per QALY gained over the status quo. In scenario analysis with 3% discounting, an ICER of AU$4758/QALY was obtained. Sensitivity analysis for the base case indicated that combined genomic screening would be cost-effective under 70% of simulations, cost-saving under 25% and not cost-effective under 5%. Threshold analysis showed that genomic screening would be cost-effective under the AU$50,000/QALY willingness-to-pay threshold at per-test costs up to AU$325 (∼£164/€192/US$208). Interpretation Our findings suggest that offering combined genomic screening for high-risk conditions to young adults would be cost-effective in the Australian public healthcare system, at currently realistic testing costs. Other matters, including psychosocial impacts, ethical and societal issues, and implementation challenges, also need consideration. Funding Australian Government, Department of Health, Medical Research Future Fund, Genomics Health Futures Mission (APP2009024). National Heart Foundation Future Leader Fellowship (102604).
Collapse
Affiliation(s)
- Paul Lacaze
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia
| | - Clara Marquina
- Health Economics and Policy Evaluation Research (HEPER) Group, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC 3052, Australia
| | - Jane Tiller
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia
| | - Adam Brotchie
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia
| | - Yoon-Jung Kang
- The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW 2011, Australia
| | - Melissa A. Merritt
- The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW 2011, Australia
| | - Robert C. Green
- Mass General Brigham, Broad Institute, Ariadne Labs and Harvard Medical School, Boston, MA, 02114, USA
| | - Gerald F. Watts
- School of Medicine, University of Western Australia, Perth, WA 6009, Australia
- Departments of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, WA, 6001, Australia
| | - Kristen J. Nowak
- Public and Aboriginal Health Division, Western Australia Department of Health, East Perth, WA, 6004, Australia
- Centre for Medical Research, The University of Western Australia, Crawley, WA, 6009, Australia
| | - Ranjit Manchanda
- Wolfson Institute of Population Health, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
- Department of Health Services Research, Faculty of Public Health & Policy, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK
| | - Karen Canfell
- The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW 2011, Australia
| | - Paul James
- Parkville Familial Cancer Centre, Peter McCallum Cancer Centre, Melbourne, VIC, 3000, Australia
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, VIC, 3050, Australia
- Department of Medicine, University of Melbourne, Parkville, VIC, 3050, Australia
| | - Ingrid Winship
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, VIC, 3050, Australia
- Department of Medicine, University of Melbourne, Parkville, VIC, 3050, Australia
| | - John J. McNeil
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia
| | - Zanfina Ademi
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia
- Health Economics and Policy Evaluation Research (HEPER) Group, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC 3052, Australia
| |
Collapse
|
7
|
Abstract
Various fundamental properties of acoustic cavitation bubbles have been investigated in single- and dual-frequency sound fields. It was found that the relative extent of bubble coalescence in the dual-frequency field correlated strongly with the synergistic enhancement of the sonochemical reaction rates. Both the relative extent of coalescence and the sonochemical synergy observed were enhanced through the addition of coalescence-inhibiting solutes. This was attributed to greater nucleation in the dual-frequency mode compared with the single-frequency modes, producing a very localized and high-density bubble field. The acoustic bubble size, compared with that measured at 355 kHz alone, was found to increase upon the application of synchronous 20 kHz pulses but was reduced dramatically when the low frequency was applied as a continuous wave. This trend is consistent with previous reports indicating that the bubble density and cavitation activity are relatively higher in the pulsed system and that the continuous wave application exerts a strong cancellation effect. The changes in bubble density and coalescence rates are proposed to govern the acoustic bubble size. The bubble lifetime was found to be longer in the dual-frequency field (>0.30 ms; >6 low-frequency oscillations, >100 high-frequency oscillations) compared with both single-frequency fields (0.26 ms and 5 oscillations for the low frequency; 0.22 ms and 75 oscillations for the high frequency). The confluence of a longer bubble lifetime and more asymmetric collapse conditions, the latter inferred from a more pronounced sodium atom emission in the sonoluminescence spectrum, resulted in a lower bubble collapse temperature measured in the dual-frequency system.
Collapse
Affiliation(s)
- Adam Brotchie
- Particulate Fluids Processing Centre, School of Chemistry, University of Melbourne, VIC 3010, Australia
| | | | | |
Collapse
|
8
|
Brotchie A, Statham T, Zhou M, Dharmarathne L, Grieser F, Ashokkumar M. Acoustic bubble sizes, coalescence, and sonochemical activity in aqueous electrolyte solutions saturated with different gases. Langmuir 2010; 26:12690-5. [PMID: 20593787 DOI: 10.1021/la1017104] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Acoustic bubble sizes, coalescence behavior, and sonochemical activity have been investigated in water in the presence of various electrolyte additives (KCl, HCl, and NaNO(3)) and saturating gases-helium, air, and argon. A strong correlation was identified between the bubble radius and the dissolved gas concentration in the cavitation medium. The extent of bubble coalescence for each gas was also studied in different electrolyte solutions. A causal relationship between coalescence and bubble size was inferred. Importantly, the effects of the different electrolytes could be completely attributed to their "salting out" effect on the dissolved gas, providing valuable insight into the contentious issue of ion-specific coalescence inhibition. Extrapolation of the bubble size data to conditions where bubble coalescence is minimal, i.e., zero gas concentration and zero ultrasound exposure time, yielded a bubble radius of 1.5 +/- 0.5 microm at an acoustic frequency of 515 kHz. In addition, the effects of electrolyte concentration and gas type on sonochemical activity were investigated. Sonochemical yields were increased by up to 1 order of magnitude at high electrolyte concentrations. This has been attributed to reduced gas and vapor content in the bubble core prior to collapse and a lower clustering density.
Collapse
Affiliation(s)
- Adam Brotchie
- Particulate Fluids Processing Centre, School of Chemistry, University of Melbourne, VIC 3010 Australia
| | | | | | | | | | | |
Collapse
|
9
|
Sonawane SH, Teo BM, Brotchie A, Grieser F, Ashokkumar M. Sonochemical Synthesis of ZnO Encapsulated Functional Nanolatex and its Anticorrosive Performance. Ind Eng Chem Res 2010. [DOI: 10.1021/ie9015039] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Shirish H. Sonawane
- Chemical Engineering Department, Vishwakarma Institute of Technology, Pune, India, and Particulate Fluids Processing Centre, School of Chemistry, University of Melbourne, Victoria 3010, Australia
| | - Boon M. Teo
- Chemical Engineering Department, Vishwakarma Institute of Technology, Pune, India, and Particulate Fluids Processing Centre, School of Chemistry, University of Melbourne, Victoria 3010, Australia
| | - Adam Brotchie
- Chemical Engineering Department, Vishwakarma Institute of Technology, Pune, India, and Particulate Fluids Processing Centre, School of Chemistry, University of Melbourne, Victoria 3010, Australia
| | - Franz Grieser
- Chemical Engineering Department, Vishwakarma Institute of Technology, Pune, India, and Particulate Fluids Processing Centre, School of Chemistry, University of Melbourne, Victoria 3010, Australia
| | - Muthupandian Ashokkumar
- Chemical Engineering Department, Vishwakarma Institute of Technology, Pune, India, and Particulate Fluids Processing Centre, School of Chemistry, University of Melbourne, Victoria 3010, Australia
| |
Collapse
|
12
|
Kanthale PM, Brotchie A, Ashokkumar M, Grieser F. Experimental and theoretical investigations on sonoluminescence under dual frequency conditions. Ultrason Sonochem 2008; 15:629-635. [PMID: 17931950 DOI: 10.1016/j.ultsonch.2007.08.006] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2007] [Revised: 07/10/2007] [Accepted: 08/22/2007] [Indexed: 05/10/2023]
Abstract
The multibubble sonoluminescence (MBSL) intensities from water exposed to the simultaneous ultrasonic irradiation from 20 kHz (fixed at 6.3 W) and 355 kHz (variable power) ultrasound sources have been compared to the MBSL from the individual ultrasound sources under the same power conditions. A synergistic enhancement of the sonoluminescence (SL) signal, >30-fold, at low powers (4.6 W) of the higher frequency was observed. At a higher acoustic power level (15.8 W) the dual frequency operation produced a decrease in the SL signal. These results are in agreement with previously reported data [P. Ciuti, N.V. Dezhkunov, A. Francescutto, F. Calligaris, F. Sturman, Ultrasonics Sonochem. 10 (2003) 337; N.V. Dezhkunov, J. Eng. Phys. Therm. 76 (2003) 142] under similar experimental conditions. Numerical single bubble (SB) dynamics calculations have been used to help interpret the experimental results. It is suggested that the observed effects are caused by a combination of changes to the peak collapse temperature of individual bubbles as well as to changes in the active bubble population.
Collapse
Affiliation(s)
- Parag M Kanthale
- Particulate Fluids Processing Centre, School of Chemistry, University of Melbourne, VIC 3010, Australia
| | - Adam Brotchie
- Particulate Fluids Processing Centre, School of Chemistry, University of Melbourne, VIC 3010, Australia
| | - Muthupandian Ashokkumar
- Particulate Fluids Processing Centre, School of Chemistry, University of Melbourne, VIC 3010, Australia.
| | - Franz Grieser
- Particulate Fluids Processing Centre, School of Chemistry, University of Melbourne, VIC 3010, Australia
| |
Collapse
|